Rituximab in psoriatic arthritis: an exploratory evaluation

Area of Science:

• Rheumatology
• Immunology
• Clinical Trials

Background:

• Psoriatic arthritis (PsA) treatments are limited, primarily including synthetic drugs and TNF inhibitors.
• Rituximab (RTX), a biological therapy effective in rheumatoid arthritis (RA), has not been previously assessed in PsA.

Purpose of the Study:

• To evaluate the efficacy and safety of rituximab (RTX) in patients with psoriatic arthritis (PsA).

Main Methods:

• An open-label study involving nine PsA patients and fourteen RA patients.
• Patients received RTX at 1000 mg twice within 14 days.
• Evaluation occurred over a 6-month period.

Main Results:

• 56% of PsA patients met PsA response criteria.
• Significant improvements were observed in DAS28 and Health Assessment Questionnaire scores for both PsA and RA patients (p≤0.05).
• The Disease Activity index for Psoriatic Arthritis showed significant improvement (p<0.05); CRP and PASI did not change significantly. RTX was well-tolerated.

Conclusions:

• Rituximab (RTX) demonstrated significant efficacy in patients with long-standing psoriatic arthritis (PsA) in this exploratory study.
• RTX may offer a new therapeutic option for PsA.
• Further randomized controlled trials are warranted to confirm RTX's efficacy in PsA.